Severe Asthma Pipeline Analysis Report 2026

Severe asthma is a complex, high-burden form of asthma that remains uncontrolled despite high-dose inhaled therapies and additional medications. According to Adrian Paul J. Rabe et al. (2023), drawing on Global Burden of Disease 2019 data, nearly 26.7% of asthma patients globally are classified as severe, highlighting a substantial unmet need. Current therapies include biologics targeting IgE, IL-5, and IL-4/13 pathways, alongside corticosteroids and bronchodilators. According to the severe asthma pipeline analysis, growing focus on precision medicine, biomarker-driven treatments, and novel biologics is expected to drive significant pipeline expansion and therapeutic advancements in the coming years.

Report Coverage

The Severe Asthma Pipeline Analysis Report gives comprehensive insights into severe asthma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Severe Asthma. The severe asthma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The severe asthma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with severe asthma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to severe asthma.

Severe Asthma Pipeline Outlook

Severe asthma is a chronic, difficult-to-control respiratory condition characterized by persistent airway inflammation, frequent exacerbations, and reduced lung function despite high-dose treatment. It occurs due to complex immune dysregulation, often involving type 2 inflammation and elevated eosinophils, leading to airway narrowing, mucus overproduction, and heightened sensitivity to environmental triggers.

Severe asthma treatment involves high-dose inhaled corticosteroids combined with long-acting bronchodilators, oral corticosteroids, and targeted biologics. Advanced therapies focus on suppressing type 2 inflammation, reducing exacerbations, and improving symptom control in refractory patients. In December 2025, GlaxoSmithKline announced United States Food and Drug Administration approval of Exdensur (depemokimab) for severe asthma with an eosinophilic phenotype. Supported by SWIFT phase III trials, the ultra-long-acting biologic demonstrated a significant reduction in annualised exacerbations and hospitalisations with twice-yearly dosing, enhancing patient adherence and outcomes.

Severe Asthma Epidemiology

The pipeline is driven by a substantial and rising epidemiological burden, particularly in terms of incidence and disease severity. According to Adrian Paul J Rabe et al., 2023, global asthma prevalence ranges from 3.44% in Asia to 8.33% in Oceania, with approximately 26.70% of cases classified as severe asthma. As per the Asthma and Allergy Foundation of America, over 28 million individuals in the United States are affected, indicating a high incidence rate. This increasing patient population continues to support innovation and advancement in targeted therapeutic development.

Severe Asthma - Pipeline Therapeutic Assessment

This section of the report covers the analysis of severe asthma drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The severe asthma pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Polymers
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Severe Asthma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 42%, covers a major share of the total severe asthma clinical trials, reflecting strong mid-stage clinical validation and a robust pipeline advancing toward commercialization. Phase III follows at 35%, indicating a significant number of late-stage candidates nearing regulatory approval. Phase IV holds 23%, supporting post-marketing expansion and real-world evidence generation. Collectively, these phases strengthen innovation, accelerate approvals, and drive sustained growth.

Severe Asthma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the severe asthma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, polymers, and peptides. The severe asthma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for severe asthma. Biologic drug therapies targeting inflammatory pathways are emerging as promising options in the severe asthma pipeline. For instance, tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, is under clinical evaluation for reducing steroid dependence. Additionally, benralizumab, an anti-eosinophilic agent, is being investigated to improve symptom control and reduce exacerbations, thereby enhancing patient outcomes and quality of life.

Severe Asthma Clinical Trials - Key Players

The report for the severe asthma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed severe asthma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in severe asthma clinical trials:

• Generate Biomedicines
• Enveda Therapeutics
• Nanjing RegeneCore Biotech Co., Ltd.
• Pfizer
• AstraZeneca
• Upstream Bio Inc.
• Incyte Corporation
• CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Mabgeek Biotech. Co. Ltd.
• Keymed Biosciences Co. Ltd.

Severe Asthma - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for severe asthma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of severe asthma drug candidates.

Drug: GB-0895

GB-0895 is an investigational biologic therapy sponsored by Generate Biomedicines, currently being evaluated in a Phase 3 clinical study for severe uncontrolled asthma. The study assesses whether adjunctive treatment with GB-0895 improves health outcomes in adolescents and adults inadequately controlled by inhaled corticosteroids and standard therapies. GB-0895 is being designed to block thymic stromal lymphopoietin (TSLP), a key cytokine driving airway inflammation, and is administered subcutaneously every six months. The randomized, double-blind trial is enrolling participants globally and is expected to be completed by January 2029.

Drug: ENV-294

ENV-294 is being evaluated in a Phase 2 clinical study sponsored by Enveda Therapeutics for adults with moderate-to-severe asthma. The study is assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy while participants are receiving background inhaled corticosteroids and long-acting beta₂-agonists. ENV-294 is a first-in-class oral small molecule targeting a novel non-kinase inflammatory pathway, aiming to improve asthma control with a favorable safety profile. Participants are administered once daily oral dosing for 12 weeks. The trial is currently recruiting and is expected to reach primary completion in December 2026, with full completion anticipated by January 2027.

Drug: RC1416

RC1416 Injection is being developed by Nanjing RegeneCore Biotech Co., Ltd. and is currently entering a Phase II clinical trial for severe uncontrolled asthma. The study is evaluating the efficacy and safety of this bispecific homodimer nanobody, which is being administered via injection. RC1416 is targeting IL-4R and IL-5 pathways, blocking IL-4, IL-5, and IL-13 signaling to reduce Th2-driven inflammation. The randomized, double-blind, placebo-controlled trial is enrolling 195 patients and is expected to be completed by February 2028, while assessing therapeutic response and tolerability.

Key Questions Answered in the Severe Asthma Pipeline Insight Report

• Which companies/institutions are leading the severe asthma drug development?
• Which company is leading the severe asthma pipeline development activities?
• What is the current severe asthma commercial assessment?
• What are the opportunities and challenges present in the severe asthma pipeline landscape?
• What is the efficacy and safety profile of severe asthma pipeline drugs?
• Which company is conducting major trials for severe asthma drugs?
• Which companies/institutions are involved in severe asthma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Severe Asthma?

Reasons To Buy This Report

The Severe Asthma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for severe asthma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from essential insights into severe asthma collaborations, regulatory environments, and potential growth opportunities.